WILMINGTON, Del.--(BUSINESS WIRE)--High-level results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated ...

Enhertu significantly improves overall survival in HER2-positive metastatic gastric cancer compared to ramucirumab and paclitaxel. DESTINY-Gastric04 is the first phase 3 trial showing Enhertu's ...

Already approved in breast, stomach and lung cancers, AstraZeneca and Daiichi Sankyo’s Enhertu has delivered a trial win across many other tumor types that express the HER2 protein biomarker. Enhertu ...

Enhertu isn’t a typical chemotherapy or immunotherapy drug but rather a combination of chemotherapy and targeted therapy, known as an antibody-drug conjugate. Enhertu works by using an antibody to ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) continued to ...

Second positive Phase III trial of AstraZeneca (AZN) and Daiichi Sankyo’s ENHERTU in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in ...

Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a median overall survival of 14.7 months Results reinforce second-line use of ENHERTU globally in this setting ENHERTU is a specifically ...

The use of Enhertu was associated with a reduction in the risk of death compared with standard chemotherapy in certain patients with gastroesophageal and gastric cancer. Patients with HER2-positive ...

When breast cancer is classified as HER2 positive, it means this cancer-driving protein is abundant on the surface of cells. The protein’s discovery led to cancers being defined in a binary way—they ...

Enhertu prolongs survival and slows tumour growth in trial First trial result in new low-HER2 breast cancer category Enhertu is antibody drug combined with cytotoxic chemical Astra to discuss review ...

We’re sorry, we are currently experiencing some issues, please try again later. Our team is working diligently to resolve the issue. Thank you for your patience and ...

After Seattle biotech Seagen paid for the rights to a HER2 breast cancer treatment in August, it got bad news a month later in the form of stellar results from a competing med. Did Seagen make a bad ...